Johnson & Johnson (NYSE: JNJ) Q2 2021 earnings call dated Jul. 21, 2021
Corporate Participants:
Christopher DelOrefice — Vice President, Investor Relations
Joseph J. Wolk — Executive Vice President, Chief Financial Officer
Jennifer Taubert — Executive Vice President, Worldwide Chairman, Pharmaceuticals
Thibaut Mongon — Executive Vice President, Worldwide Chairman, Consumer Health
Ashley McEvoy — Executive Vice President, Worldwide Chairman, Medical Devices
Paul Stoffels — Vice Chairman of the Executive Committee and Chief Scientific Officer
Analysts:
Louise Chen — Cantor Fitzgerald Securities — Analyst
Larry Biegelsen — Wells Fargo Securities LLC — Analyst
Chris Schott — J.P. Morgan Securities LLC — Analyst
Bob Hopkins — BofA Securities, Inc. — Analyst
Joshua Jennings — Cowen and Company — Analyst
Terence Flynn — Goldman Sachs & Co. LLC — Analyst
Matt Miksic — Credit Suisse Securities (USA) LLC — Analyst
Joanne Wuensch — Citi — Analyst
Jayson Bedford — Raymond James Financial Inc. — Analyst
_________
To read the full earnings call transcript, click here
Most Popular
Earnings Preview: Accenture (ACN) likely had a strong start to fiscal 2025
For Accenture plc. (NYSE: ACN), 2024 was a fruitful year marked by positive financial performance. The professional service firm effectively navigated a challenging market environment leveraging its agile business model
Signet Jewelers (SIG): Fashion remains a strong point for the jewelery retailer
Shares of Signet Jewelers Limited (NYSE: SIG) were down over 3% on Tuesday. The stock has dropped 12% over the past three months. The company faced challenges in the third
Pfizer (PFE) reaffirms FY24 forecast; provides FY25 guidance
Pharmaceutical company Pfizer Inc. (NYSE: PFE) Tuesday reaffirmed its financial outlook for fiscal 2024 and provided guidance for fiscal 2025. The company said it achieved the goal of $4 bln
Listen On
